Al-saffar et al. 24 showed that treatment of prostate cancer cells with the PI3K inhibitor, PI-103 which caused G1 cell cycle arrest and decreased Akt phosphorylation was accompanied by decreased PCho concentration. Here, AKT1 is linked to prostate carcinoma.